Back to News
investment

Why Celcuity Stock Popped on Monday

newsfeedback@fool.com (Eric Volkman)
Loading...
3 min read
0 likes
⚡ Quantum Brief
On the brink of a decision Well before market open, Citizens pundit Silvan Turkcan launched his tracking of Celcuity stock. That initial report on the company was quite bullish, hence the positive investor reaction. According to reports, Turkcan's analysis centers -- not surprisingly -- on gedatolisib, its investigational drug that targets advanced breast cancer. The medication is less than two months away from the date the Food and Drug Administration (FDA) has set to complete its review of the company's New Drug Application (NDA) for it.
AI Audio Summary
0:00 / 0:00
Click to play
ChatGPT Image Nov 30, 2025, 05_45_25 PM.png
Quantum News · Media Library

By Eric Volkman – Apr 27, 2026 at 6:18PM ESTKey PointsIt's clinical-stage at the moment, but might not stay that way for much longer.The company's leading drug candidate could win approval in less than two months.One of the livelier biotech stocks on the market Monday was Celcuity (CELC +3.77%), which saw its share price leap nearly 4% higher thanks to the initiation of coverage by an analyst. That initial report on the company was quite bullish, hence the positive investor reaction. On the brink of a decision Well before market open, Citizens pundit Silvan Turkcan launched his tracking of Celcuity stock. He rates the clinical-stage biotech a market outperform (i.e., buy) and has set a $150-per-share price target. That's nearly 20% above the company's latest closing level and is one of the higher price targets among analysts following Celcuity. Image source: Getty Images. According to reports, Turkcan's analysis centers -- not surprisingly -- on gedatolisib, its investigational drug that targets advanced breast cancer. The medication is less than two months away from the date the Food and Drug Administration (FDA) has set to complete its review of the company's New Drug Application (NDA) for it. The analyst pointed out that gedatolisib, one of the more promising oncology drugs currently under review, could eventually be approved for other indications besides breast cancer. That alone would give not only significant value to the drug but also to its developer. ExpandNASDAQ: CELCCelcuityToday's Change(3.77%) $4.56Current Price$125.59Key Data PointsMarket Cap$5.9BDay's Range$121.70 - $129.1052wk Range$9.51 - $129.10Volume28KAvg Vol746K A hot biotech in a hot segment Any potential blockbuster cancer drug won't go ignored by market players for long. Celcuity is on many a biotech investor's radar due to gedatolisib's sky-high potential and its fine shot at FDA approval in the very near future. While the stock is expensive, its leading drug candidate's potential alone could further increase its value. I'd still be a buyer of this stock.Read NextApr 27, 2026 •By Prosper Junior BakinyIs This Deal a Game Changer for Novo Nordisk?Apr 27, 2026 •By Prosper Junior BakinyAre These Beaten-Down Stocks Generational Opportunities or Value Traps?Apr 27, 2026 •By Prosper Junior BakinyForget Weight Loss Drugs: Here's An Even Better Reason to Invest in Eli LillyApr 27, 2026 •By Prosper Junior Bakiny3 Healthcare Stocks That Pay You While You Wait for the GrowthApr 27, 2026 •By Josh Kohn-LindquistStock Market Today, April 27: Organon Shares Surge After Sun Pharma Agrees to Acquire Company in All Cash DealApr 27, 2026 •By James BrumleyWhy Sagimet Biosciences Stock Is Soaring TodayAbout the AuthorEric Volkman is a contributing Motley Fool finance and stock market analyst. Previously, Eric was an equities analyst at European investment bank Raiffeisen Capital and Investment. He’s also been a freelance finance writer since 1995. He studied at Susquehanna University.TMFVolkmanStocks MentionedCelcuityNASDAQ: CELC$125.59(+3.77%)+$4.56*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Read Original

Source Information

Source: The Motley Fool

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.